A
Avidity Biosciences
Research, development, and manufacturing of drug candidates which include antibody-sirna complexes
At a glance
- Founded
- 2013
- Headquarters
- San Diego, United States
- Listing
- IPO 2020
- Sector
- Biotech & Life Sciences
- Power Law
- Decacorn$10B+ valuation tier
Knowledge graph
More headlines
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later18 investors entered at this stage
- TATakeda
Cormorant Asset Management
F-Prime- BPBrace Pharma
Janus Henderson Investors- AMAlethea Capital Management
- ACAdage Capital
- FMFarallon Capital Management
- ELEli Lilly
Perceptive Advisors- ECEcoR1 Capital
Wellington Management- BCBoxer Capital
Casdin Capital- LCLogos Capital
- MPMoore Venture Partners
RA Capital Management- RIRTW Investments
Source: Dealroom Talent Intelligence.
Alumni founders
Former Avidity Biosciences employees who went on to found companies, sorted by Dealroom signal score.
MBMBX BiosciencesEst. 2018
P. Kent HawrylukUnited States
BRBridgeBioEst. 2014
Frank McCormickUnited States
KOKura OncologyEst. 2014
Troy WilsonUnited States
RBReplicate BioscienceEst. 2021Global footprint
team presence
across markets
Patents
39 active patent families included in this estimate.
A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.
Market sentiment
An AI-synthesised read of the highest-engagement posts about Avidity Biosciences on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Avidity Biosciences on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.